Sugi Predict

Sugi Predict / Compounds / SCHEMBL5480877

SCHEMBL5480877

SCHEMBL5480877

N#Cc1cc(Cl)ccc1-n1cnnn1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 3/20 0.49
▸ F2 P00734 1/20 0.49
▸ SCN9A Q15858 1/20 0.43
▸ ALDH1A1 P00352 5/20 0.41
▸ F11 P03951 4/20 0.39
▸ KLK1 P06870 1/20 0.39
▸ KMT2A Q03164 3/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ KLKB1 P03952 1/20 0.38
▸ USP2 O75604 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ KCNJ1 P48048 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29792818 1.00 NOTUM (0.49) NOTUMF2SCN9AALDH1A1F11
SCHEMBL11117017 0.78 NOTUM (0.56) NOTUMF2ALDH1A1KMT2AKDM4E
SCHEMBL16122376 0.78 KCNJ1 (0.45) ALDH1A1KMT2AKDM4ENPSR1TSHR
SCHEMBL6078473 0.78 NOTUM (0.51) NOTUMSCN9AALDH1A1KMT2AKDM4E
SCHEMBL1611233 0.78 KCNJ1 (0.54) ALDH1A1KMT2AKDM4ENPSR1TSHR
SCHEMBL1612316 0.77 ALDH1A1 (0.36) NOTUMF2SCN9AALDH1A1F11
SCHEMBL1197336 0.77 F11 (0.49) NOTUMF2F11KLK1KMT2A
SCHEMBL1612315 0.77 ALDH1A1 (0.36) NOTUMF2SCN9AALDH1A1F11
SCHEMBL4926658 0.77 ALDH1A1 (0.53) NOTUMF2ALDH1A1KMT2AKDM4E
SCHEMBL23747882 0.76 NOTUM (0.40) NOTUMF2SCN9AALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12221441-B2 Plasma kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-11 — — US disclosed
EP-4477220-A2 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF Takeda Pharmaceutical Company Limited (JP) 2024-12-18 — — EP disclosed
EP-4031547-B1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2024-07-17 — — EP disclosed
EP-4031547-B1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2024-07-17 — — EP disclosed
US-20240199612-A1 IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES (US) 2024-06-20 — — US disclosed
EP-4308227-A1 IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 — — EP disclosed
CN-117396473-A Imidazopyridinyl inhibitors of plasma kallikrein 武田药品工业株式会社 2024-01-12 — — CN disclosed
US-20230391773-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-07 — — US disclosed
US-11787796-B2 Plasma Kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-17 — — US disclosed
US-11787796-B2 Plasma Kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-17 — — US disclosed
US-20210078999-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF CHARLES RIVER LABORATORIES, INC. 2021-03-18 — — US disclosed
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 — — US disclosed
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 — — US disclosed
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 — — US disclosed
US-7144899-B2 Thrombin inhibitors MERCK & CO., INC. (US) 2006-12-05 — — US disclosed
WO-2005040137-A1 AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-05-06 — — WO disclosed
WO-2005040137-A1 AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-05-06 — — WO disclosed
WO-2004032834-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2004-04-22 — — WO disclosed
US-20040073025-A1 Thrombin inhibitors MERCK SHARP & DOHME CORP. 2004-04-15 — — US disclosed
WO-2002064559-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12221441-B2 Plasma kallikrein inhibitors and uses thereof KLKB1, KLK1, KLK5 NOTUM 531/4885F2 25/4885SCN9A 3603/4885
US-11787796-B2 Plasma Kallikrein inhibitors and uses thereof KLKB1, KLK1, KLK5 NOTUM 531/4885F2 25/4885SCN9A 3603/4885
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors F2, F12, SERPINC1 NOTUM 2783/4885F2 1/4885SCN9A 3829/4885
US-20240199612-A1 IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK1, KLK4 NOTUM 1321/4885F2 32/4885SCN9A 3653/4885
US-20040073025-A1 Thrombin inhibitors F2, F11, F10 NOTUM 1633/4885F2 1/4885SCN9A 1729/4885
US-20230391773-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF KLKB1, KLK1, KLK5 NOTUM 531/4885F2 25/4885SCN9A 3603/4885
US-20210078999-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF KLKB1, KLK1, KLK5 NOTUM 531/4885F2 25/4885SCN9A 3603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.